Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
Public ClinicalTrials.gov record NCT01261793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE).
Study identification
- NCT ID
- NCT01261793
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 791 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- May 2015 (Actual)
- Completion
- Jun 2015 (Actual)
- Last update posted
- Dec 4, 2020
2010 – 2015
United States locations
- U.S. sites
- 49
- U.S. states
- 24
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 539 | Birmingham | Alabama | — | — |
| 557 | Little Rock | Arkansas | — | — |
| 515 | Hemet | California | — | — |
| 544 | Huntington Beach | California | — | — |
| 550 | La Jolla | California | — | — |
| 548 | Los Angeles | California | — | — |
| 589 | San Diego | California | — | — |
| 531 | San Leandro | California | — | — |
| 558 | Torrance | California | — | — |
| 594 | Westlake Village | California | — | — |
| 532 | Denver | Colorado | — | — |
| 511 | Bridgeport | Connecticut | — | — |
| 514 | Brandon | Florida | — | — |
| 533 | Fort Lauderdale | Florida | — | — |
| 518 | Plantation | Florida | — | — |
| 585 | Port Orange | Florida | — | — |
| 538 | Tampa | Florida | — | — |
| 537 | Atlanta | Georgia | — | — |
| 587 | Decatur | Georgia | — | — |
| 590 | Idaho Falls | Idaho | — | — |
| 543 | Bowling Green | Kentucky | — | — |
| 592 | Lexington | Kentucky | — | — |
| 576 | New Orleans | Louisiana | — | — |
| 572 | Boston | Massachusetts | — | — |
| 554 | Ann Arbor | Michigan | — | — |
| 513 | Lansing | Michigan | — | — |
| 599 | Lansing | Michigan | — | — |
| 575 | Florissant | Missouri | — | — |
| 549 | St Louis | Missouri | — | — |
| 596 | Nashua | New Hampshire | — | — |
| 593 | Clifton | New Jersey | — | — |
| 568 | Freehold | New Jersey | — | — |
| 551 | Brooklyn | New York | — | — |
| 553 | Lake Success | New York | — | — |
| 545 | Manhasset | New York | — | — |
| 577 | Roslyn | New York | — | — |
| 559 | Charlotte | North Carolina | — | — |
| 547 | Tulsa | Oklahoma | — | — |
| 561 | Wyomissing | Pennsylvania | — | — |
| 535 | Charleston | South Carolina | — | — |
| 598 | Myrtle Beach | South Carolina | — | — |
| 571 | Jackson | Tennessee | — | — |
| 574 | Amarillo | Texas | — | — |
| 570 | Austin | Texas | — | — |
| 541 | Houston | Texas | — | — |
| 563 | Houston | Texas | — | — |
| 562 | San Antonio | Texas | — | — |
| 552 | Chesapeake | Virginia | — | — |
| 534 | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01261793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01261793 live on ClinicalTrials.gov.